. [82] to assess the efficacy, security and tolerability of Cannabidiol being an adjunct therapy in addition to anti-epileptic medication on the patients suffering from tuberous sclerosis intricate whose most frequent neurological symptom is epilepsy. With this clinical trial study, just after procedure with Cannabidiol, responder rate of the indiv